Repligen (NASDAQ:RGEN) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Repligen (NASDAQ:RGEN) in a report issued on Thursday, Benzinga reports. The firm currently has a $205.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a buy rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an overweight rating and a $180.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a hold rating to a buy rating and cut their price target for the company from $180.00 to $155.00 in a report on Wednesday, June 26th. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company an overweight rating in a report on Wednesday, July 31st. Finally, Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They set a neutral rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $190.25.

Repligen Stock Down 0.8 %

RGEN stock opened at $145.93 on Thursday. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.17 billion, a price-to-earnings ratio of 583.74, a PEG ratio of 4.23 and a beta of 0.94. The company has a 50 day moving average of $148.80 and a two-hundred day moving average of $153.44.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The company’s revenue was down 3.2% compared to the same quarter last year. On average, equities analysts anticipate that Repligen will post 1.45 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Several large investors have recently made changes to their positions in the business. Andra AP fonden acquired a new position in Repligen in the 2nd quarter valued at approximately $25,000. YHB Investment Advisors Inc. acquired a new position in Repligen in the 1st quarter valued at approximately $26,000. International Assets Investment Management LLC acquired a new position in Repligen in the 2nd quarter valued at approximately $33,000. Lazard Asset Management LLC raised its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new position in Repligen in the 2nd quarter valued at approximately $57,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.